Latest Hydroxyethyl starch Stories

Starch-based intravenous (IV) fluids used by the NHS to treat seriously ill patients are causing unnecessary deaths, according to a new Cochrane systematic review by researchers at the London School of Hygiene & Tropical Medicine. Based on data from 25 randomized control trials, the researchers concluded that starch-based colloid fluids, used to stabilize patients with low blood pressure, are not only more expensive than saline-based crystalloid fluids, but may also be causing around...

In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch, compared with other resuscitation solutions, was not associated with decreased mortality, according to an article appearing in the February 20 issue of JAMA. Moreover, after exclusion of 7 trials performed by an investigator whose research has been retracted because of scientific misconduct, the analysis of the remaining studies...

SYDNEY, Oct. 17, 2012 /PRNewswire/ -- A landmark study by Australian and New Zealand researchers has found that a widely used starch fluid for resuscitation of patients in intensive care units (ICUs) provides no clinical benefit and its use results in increased acute kidney failure (haemodialysis) when compared to normal saline. The findings of CHEST (The Crystalloid vs Hydroxyethyl Starch Trial) have the potential to change the way patients are treated in ICUs across the world....

SYDNEY, Oct. 17, 2012 /PRNewswire/ -- Results of a landmark study by Australian and New Zealand researchers comparing starch fluid for resuscitation of patients in intensive care units (ICUs) has shown that it has significant impact on patients when compared to normal saline. The findings of CHEST (The Crystalloid vs Hydroxyethyl Starch Trial) will be published tomorrow in the New England Journal of Medicine and will change the way patients are treated in ICUs across the world....

BAD HOMBURG, Germany and LACHEN, Switzerland, Oct. 28 /PRNewswire/ -- Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein. Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Octapharma. This technology platform is based on hydroxyethyl starch ("HES") which will be combined with a recombinant protein from...